Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

aTyr Completes $23 Million Funding for Physiocrine Drugs

publication date: Oct 26, 2010

aTyr Pharma completed a $23 million Series C round, which it will use to develop its pre-clinical pipeline, based on physiocrine drugs. The company is headquartered in San Diego. It also has operations in Shanghai and collaborates with China organizations in drug development. In addition, aTyr's Hong Kong subsidiary, Pangu BioPharma, which operates in partnership with Hong Kong University of Science and Technology (HKUST), assists in aTyr's pre-clinical drug development. More details....



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital